What is BioCision?
BioCision operates as a specialized entity within the Research & Development industry, focusing on the critical intersection of biopharma services and laboratory innovation. With a workforce of 20 to 49 professionals and annual revenues ranging between 10M and 25M, the company maintains a lean, high-impact operational model. Its market position is defined by its ability to provide essential infrastructure and technical expertise to the broader life sciences ecosystem, facilitating advancements in drug development and laboratory efficiency. By maintaining a headquarters in Pittsburgh, Pennsylvania, BioCision leverages regional talent to drive its mission of optimizing complex research workflows.
How much funding has BioCision raised?
BioCision has raised a total of $10.4M across 3 funding rounds:
Private Equity
$2.1M
Private Equity
$2.5M
Private Equity
$5.8M
Private Equity (2012): $2.1M with participation from BroadOak Capital Partners and Research Corporation Technologies, Inc.
Private Equity (2012): $2.5M, investors not publicly disclosed
Private Equity (2014): $5.8M supported by Brooks Automation, Inc.
Key Investors in BioCision
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies. The firm focuses on life sciences tools, diagnostics, and biopharma services, leveraging its in-house expertise to deliver growth capital.
Research Corporation Technologies, Inc.
Research Corporation Technologies develops specialized expression technology and provides licensing for commercial applications in the life sciences sector. The firm focuses on enabling technologies that simplify purification and support vaccine platform development.
Brooks Automation, Inc.
Brooks Automation provides innovative technologies and manufacturing process efficiencies designed to drive performance and value. The firm is a key player in the automation space, supporting the future of high-tech manufacturing and laboratory operations.
What's next for BioCision?
Looking ahead, the recent capital injection is expected to catalyze BioCision's strategic initiatives, particularly in the areas of process optimization and market expansion. Given the company's history of securing private equity, the current lifecycle stage suggests a transition toward enterprise-level scaling. Management is likely to prioritize the integration of advanced R&D technologies and the strengthening of its service portfolio to meet the increasing demands of the biopharma sector. As the company continues to mature, the focus will remain on leveraging its existing partnerships and technical capabilities to capture a larger share of the life sciences services market, ensuring long-term sustainability and competitive advantage.
See full BioCision company page
